## ICMJE DISCLOSURE FORM

Date	e:		8/17/2023		
Your Name:			Hong Liao		
Manuscript Title:			The dedicator of cytokinesis 6 (DOCK6) is a novel indicator for prognosis in cervical cancer		
Mar	nuscript Number (if	known):	GPM-23-13	,	
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the ma indicate a bias. If you are in doub			re ask you to disclose all relationships/activities/interests listed below that are related to the lated" means any relation with for-profit or not-for-profit third parties whose interests may be anuscript. Disclosure represents a commitment to transparency and does not necessarily of about whether to list a relationship/activity/interest, it is preferable that you do so.  ies/interests should be defined broadly. For example, if your manuscript pertains to the		
	iemiology of hyperte medication is not m			acturers of antihypertensive medication, even if	
In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.			ithout time limit. For all other items, the time		
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			_ ,	Company (Company of the Company of t	
The state of the s			I ime frame: Since the initial planning	of the work	
The state of the s	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.		Time frame: Since the initial planning	Click the tabling to add entational rows.	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for			Click the tabling to add entational rows.	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	⊠ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	⊠ None	

 $oxed{\square}$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## **ICMJE DISCLOSURE FORM**

Dat	e:	8/17/2023			
Your Name:		Quyon Wang			
Manuscript Title:		The dedicator of cytokinesis 6 prognosis in cervical cancer	The dedicator of cytokinesis 6 (DOCK6) is a novel indicator for prognosis in cervical cancer		
Ma	nuscript Number (if know	): GPM-23-13			
con affe	tent of your manuscript. ected by the content of th	, we ask you to disclose all relationships/activition. Related" means any relation with for-profit or not manuscript. Disclosure represents a commitme bubt about whether to list a relationship/activity.	ot-for-profit third parties whose interests may be nt to transparency and does not necessarily		
epi		*	example, if your manuscript pertains to the acturers of antihypertensive medication, even if		
	tem #1 below, report all s me for disclosure is the pa	pport for the work reported in this manuscript w t 36 months.	vithout time limit. For all other items, the time		
		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initial planning	g of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Time frame: Since the initial planning	Click the tab key (sauld additional rows,		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	. Takin jira (i. 12) (it) = nesetle en kanva ( )   Ali Telefo, il a vedicini	Click the tab key readil-additional rows,		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	None	Click the tab key readil-additional rows,		

WESTER BUILDING FOR

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	⊠ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	■ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	I⊠     None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	☑ None	

 $\square$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

Date:		8/17/2023			
Your Name:		Juan Zou			
Manuscript Title:		The dedicator of cytokinesis 6 prognosis in cervical cancer	The dedicator of cytokinesis 6 (DOCK6) is a novel indicator for prognosis in cervical cancer		
Ma	nuscript Number (if known):	GPM-23-13			
content of your manuscript. "Rel affected by the content of the ma					
epi		ou should declare all relationships with manuf	ies/interests should be defined broadly. For example, if your manuscript pertains to the ou should declare all relationships with manufacturers of antihypertensive medication, even if I in the manuscript.		
	tem #1 below, report all supp me for disclosure is the past 3	A STATE OF THE PARTY OF THE PAR	vithout time limit. For all other items, the time		
		all entities with whom you have this nship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
1000					
		Time frame: Since the initial planning	; of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Time frame: Since the initial planning	of the work  Click the tablesy to add additional cows.		
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None  Time frame: past 36 mont	Click the tables to and additional cows.		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Click the tables to and additional cows.		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	⊠ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel		
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠  None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	□ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	

 $oxed{\square}$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.

		ICMJE DISCLOSURE FORM
Date	:	8/17/2023
Your Name:		I Xim Tan
Man	uscript Títle:	The dedicator of cytokinesis 6 (DOCK6) is a novel indicator for prognosis in cervical cancer
Man	uscript Number (if	n): GPM-23-13
cont affect indice The epid that	ent of your manuscicted by the content cate a bias. If you are author's relationship emiology of hyperte medication is not medication is not medication.	y, we ask you to disclose all relationships/activities/interests listed below that are related to the 'Related' means any relation with for-profit or not-for-profit third parties whose interests may be manuscript. Disclosure represents a commitment to transparency and does not necessarily oubt about whether to list a relationship/activity/interest, it is preferable that you do so.  civities/interests should be defined broadly. For example, if your manuscript pertains to the you should declare all relationships with manufacturers of antihypertensive medication, even if ned in the manuscript.  Support for the work reported in this manuscript without time limit. For all other items, the time at 36 months.
		ne all entities with whom you have this Specifications/Comments (e.g., if payments were tionship or indicate none (add rows as needed) made to you or to your institution)
		Time frame: Since the initial planning of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Click the tab key related additional rows.
		Time frame: past 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None
3	Royalties or licenses	None

TOTAL DESIGNATION COMM

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	

 $\square$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.